Prognostic analysis revealed that, although not statistically significant, the immune-inflamed group defined by iTIL score showed a trend toward improved PFS (hazard ratio, 0.73; 95% CI, 0.39–1.36; p = 0.32) and OS (hazard ratio, 0.86; 95% CI, 0.41–1.83; p = 0.70) (Fig. 3 C), which was in contrast to the prognostic findings based on transcriptome-based immune classification.
For both groups combined, the mean BOLD percent signal change within the largest cluster (the right posterior insula (48 voxels surrounding 48-3 3) showed a trend-level positive correlation with the Sensory Profile composite variable indexing unusual eating habits or food preferences generally ( P = .321, P = .060).
Efficacy analysis The difference in time to resolution of all influenza-like symptoms between treatment groups was not statistically significant but showed a trend towards improvement in subjects in the inosine pranobex group compared with subjects in the placebo group (HR: 1.175; 95 % CI: 0.806, 1.714; p = 0.324) (Fig. 2 ).
While obese patients showed a trend toward direct admission to the operating room at 36% compared to 29% in the non-obese group, there was no statistically significant difference ( p =0.324).
In the GSE41613 data, the 23-gene signature score was significantly prognostic for both OS ( P = 0.002; Fig 9H ) and DSS ( P < 0.001; Figs 9I and S6D – S6F and S15 Table ), whereas for the GSE42743 data, the score showed a trend of predicting worse OS ( P = 0.326; Fig 9J ) and was prognostic for DSS ( P = 0.021; Figs 9K and S6G – S6H and S15 Table ).
GAS5 in exosomes showed a trend toward an association with ED (OR = 1.0976, 95% CI: 0.9111 to 1.3223, p = 0.327), although this result did not reach significance.
The patients who reached ESRD showed a trend of worsening renal function at renal biopsy (37.31 [21.04–51.25] vs 67.08 [25.25–113.28] ml/min/1.7m 2 , p = 0.328).
Consequently, the cumulative DLP values for the entire intervention showed a trend ( p = 0.328) to be lower in the years 2013–2020 (623.0 [445.0; 822.0] mGy·cm) compared to the years 2005–2012 (811.5 [502.3; 1061.5] mGy·cm). 3.2.
Also the cluster of abdominal complications showed a trend towards fewer complications in the SG (22 complications versus 29 complications, P = 0.328), but without reaching statistical significance, as illustrated in Figure 3 a.
Using the “High DDS and High PA” group as the reference, the fully adjusted model revealed: the “High DDS and Low PA” group exhibited significantly lower MMSE scores by 1.12 points (β = −1.12, 95% CI: −1.94 to −0.30, P = 0.008); the “Low DDS and Low PA” group demonstrated significantly lower MMSE scores by 1.20 points (β = −1.20, 95% CI: −2.04 to −0.36, P = 0.005); the “Low DDS and High PA” group showed a trend toward lower MMSE scores that did not reach statistical significance (β = −0.51, 95% CI: −1.55 to 0.52, P = 0.330).
TT showed a trend of decreased risk of ST when compared with OAC plus clopidogrel/aspirin (OR: 0.78, 95% CI: 0.46–1.30, P = 0.33) and OAC plus aspirin (OR: 0.40, 95% CI: 0.15–1.11, P = 0.08), whereas no differences in TT and OAC plus clopidogrel (OR: 1.14, 95% CI: 0.54–2.40, P = 0.73).
negative) showed a trend for a prognostic difference in BCM with 10-year FU (HR 0.56, 95% CI 0.17–1.8), but the evidence was very weak ( P = 0.33), and the effect was lost when analyzed with 25-year FU (HR 0.93, 95% CI 0.29-3.0, P = 0.90) (Table 4 ; Online Resource 1).
When evaluated as single, independent variables in relation to thalamic volume, however, neither duration nor BTX dose showed a trend or significance (R = 0.25, p = 0.33 and R = 0.042, p = 0.87, respectively).
LA-ESV did not significantly change even though it showed a trend in decreasing starting from 76 mL (IQR: 57–97) to 74 mL (IQR: 59–97) ( p = 0.331).
The ORRs were not significantly different, but the NIVO+IPI ≤2 cycles group showed a trend toward a higher ORR than the NIVO+IPI ≥3 cycles group (25.0% vs 13.8%, p = 0.331) (Table 3 ).
Accordingly, although there were overlapping CIs for hazard rate ratios, the difference in risk of CV death between ACEI-treated patients with ischemic versus non-ischemic CHF, showed a trend for increased risk of CV death with increasing score A in patients with ischemic CHF (P = 0.332 [ Fig 4 ]).
In addition, the lowest TG (<1.17 mmol/l), lowest LDL-C group (<2.24 mmol/l), and highest HDL-C (>1.11 mmol/l) tertiles showed a trend in association with an increased risk of NOAF ( P =0.333; P =0.059; P =0.090, respectively).
Regarding NLR, although the low NLR group showed a trend toward improved PFS (33.57 ± 2.78 months vs. 30.03 ± 1.84 months, P = 0.333, Figure 3C ) and OS (41.35 ± 0.63 months vs. 38.92 ± 1.49 months, P = 0.262, Figure 3D ), these differences were not statistically significant.
In the MM subgroup, the difference in LOS, although not statistically significant, showed a trend toward longer stays in malnourished patients (39.00 days vs. 18.03 days, p = 0.3337) (Figure 1 ).
Although not statistically significant, mSRF and fSRF showed a trend of reduction during the follow-up (from 141 ± 77 to 111 ± 120 μm ( p = 0.334) and from 101 ± 79 to 87 ± 129 μm ( p = 0.565) for mSRF and fSRF, respectively).
Although EDV and ESV showed a trend toward reduction (EDV: 176.2 ± 64.9 ml at baseline to 167.6 ± 31.1 ml at 12 months, P = 0.335; ESV: 124.5 ± 52.7 ml at baseline to 116.8 ± 24.6 ml at 12 months, P = 0.606), these changes were not statistically significant.
The follow-up analysis of urine concentrations of the [TIMP-2] [IGFBP7] comparisons in group 1 (obstructive HN) between the preoperative sample (0.29; 0.10-0.85) and postoperative follow-up sample (0.29; 0.16-0.65) showed a trend of stability in these values (p=0.335) ( Table-2 ).
Hispanic patients showed a trend towards higher odds of receiving DBS (AOR 1.25, 95% CI 0.80–1.94, p = 0.337) but this was not statistically significant.
In the steroid group, patients who successfully maintained the imatinib dosage showed a trend toward more favorable survival outcomes than those who did not (3-year PFS, 73.3% vs. 44.4%, p = 0.34; 3-year OS, 95.8% vs. 75.0%, p = 0.15, respectively).
Stage II AC showed a trend towards worse outcomes with adjuvant therapy with 5-year survival of 81% for observation vs 55% for adjuvant therapy ( P = 0.34), however, without statistical significance potentially owing to the few patients available for analysis.